๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Zhangzhou
Clinical trial register · China

Clinical Trials in Zhangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Capital Medical University7 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.3 Fujian Provincial Hospital3 Fujian Maternity and Child Health Hospital3 Bristol-Myers Squibb2
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Zhangzhou

42 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Radical Surgery Versus Non-Surgery in Gastric Cancer Patients With Peritoneal Metastasis After Successful Conversion Therapy
NCT07789184Gastric Cancer, Peritoneal Metastasis
Hua Huang, MD, PhD
Phase 3
170
Beijing, Chongqing, Zhangzhou, Guangzhou, Wuhan, Nanjing, Nantong, Nanchang
2026-10-01
Not yet open
A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer
NCT07771764ALK-positive Non Small Cell Lung Cancer
First Affiliated Hospital of Fujian Medical University
Phase 2
30
Fuzhou, Longyan, Quanzhou, Xiamen, Zhangzhou
2026-08-01
Not yet open
Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)
NCT07668960High-grade Squamous Intraepithelial Lesions of the Cervix Associated With Human Papillomavirus (HPV) Type 16 and/or HPV Type 18 Infection
Shanghai Mianyi Biopharmaceutical Co., Ltd.
Phase 1/2
60
Beijing, Chongqing, Zhangzhou, Jinan
2026-06-17
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Active, closed
Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)
NCT07513233Acute Ischemic Stroke
Capital Medical University
Phase 1
92
Zhangzhou, Jiuquan, Yulin, Shangqiu, Xuzhou, Beijing, Zibo, Huzhou
2026-04-28
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 โ‰ฅ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Not yet open
Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07464587Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
800
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2026-03
Recruiting
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
NCT07256236Cervical Cancer
Fujian Cancer Hospital
Phase 2
89
Fuzhou, Zhangzhou, Guangzhou, Nanning, Hohhot, Dalian, Jinan, Jining
2026-01-28
Active, closed
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776Acute Ischemic Stroke
Capital Medical University
Phase 3
692
Suzhou, Zhangzhou, Qinzhou, Langfang, Qinhuangdao, Tangshan, Harbin, Anyang
2025-12-05
Recruiting
A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.
NCT07258979Recurrent or Metastatic Nasopharyngeal Carcinoma
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2
202
Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Guangzhou, Jiangmen, Shaoguan
2025-11-05
Recruiting
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
NCT07296705Muscle Invasive Bladder Cancer (MIBC)
Fujian Medical University Union Hospital
Phase 2
25
Fuzhou, Putian, Quanzhou, Sanming, Xiamen, Zhangzhou, Nanchang, Jinan
2025-10-25
Recruiting
Balloon Guide Catheter to Optimize Outcomes in Stroke Thrombectomy of the Internal Carotid Artery
NCT07192029Stroke
Xuanwu Hospital, Beijing
Not applicable
364
Fuzhou, Zhangzhou, Beijing
2025-10-12
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2
NCT07139314Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
240
Maโ€™anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-24
Recruiting
JS207 Combination Therapy in Triple-negative Breast Cancer
NCT07045311Triple-negative Breast Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2
80
Hefei, Beijing, Guangzhou, Baoding, Harbin, Zhangzhou, Wuhan, Nanjing
2025-09-17
Recruiting
A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer
NCT07043725HER2-positive Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
544
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Quanzhou, Xiamen, Zhangzhou
2025-09-15
Recruiting
A Study of Pegmolesatide of in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)
NCT07136792Renal Anemia of Chronic Kidney Disease
Guangdong Provincial People's Hospital
Not applicable
96
Beijing, Longyan, Zhangzhou, Guangzhou, Meizhou, Shantou, Shaoguan, Zhongshan
2025-09-08
Recruiting
Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation
NCT07139301Ischemic Stroke, Atrial Fibrillation
Capital Medical University
Not applicable
438
Maโ€™anshan, Beijing, Zhangzhou, Heyuan, Qinzhou, Baoding, Harbin, Jiamusi
2025-09-04
Not yet open
Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease
NCT07147946Chronic Obstructive Pulmonary Disease
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
666
Bozhou, Chizhou, Hefei, Chongqing, Fuzhou, Zhangzhou, Lanzhou, Foshan
2025-09
Not yet open
A Phase III Clinical Study of H077 Sustained-Release Tablets Compared With Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
NCT07146386Benign Prostatic Hyperplasia, Benign Prostatic Hyperplasia With Lower Urinary Tract Symptoms
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 3
728
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Dongguan, Shantou
2025-08
Recruiting
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263Small Cell Lung Cancer
Akeso
Phase 3
560
Beijing, Beijin, Chongqing, Fuzhou, Longyan, Zhangzhou, Lanzhou, Jiangmen
2025-06-13
Recruiting
TQC2731 Clinical Trial for the Treatment of Severe Asthma With Injection
NCT06829784Asthma
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
660
Bozhou, Hefei, Lu'an, Tongling, Beijing, Xiamen, Zhangzhou, Lanzhou
2025-03-21
Recruiting
Two-cycle and Three-cycle Induction Therapy With Modified TPF Regimen Combined and Camrelizumab for LANPC
NCT06811844Nasopharyngeal Neoplasms, PD-1 Inhibitor, Induction Therapy, Complete Response
The First Affiliated Hospital of Xiamen University
Phase 2
208
Xiamen, Zhangzhou, Haikou
2025-02-25
Recruiting
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
NCT06761027Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
Fujian Provincial Hospital
Phase 1/2
29
Fuzhou, Zhangzhou
2024-12-23
Recruiting
Normobaric Oxygen in AIS Transferred for EVT
NCT06666764Ischemic Stroke
Capital Medical University
Phase 3
1,500
Beijing, Fuzhou, Ningde, Putian, Zhangzhou, Guangzhou, Hezhou, Cangzhou
2024-12-13
Active, closed
A Clinical Trial of TQB2102 for Injection in the Treatment of HER2 Low-Expressing Recurrent/Metastatic Breast Cancer
NCT06561607Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
542
Bengbu, Hefei, Beijing, Quanzhou, Zhangzhou, Lanzhou, Wuwei, Guangzhou
2024-10-11
Active, closed
Regular Physical Exercise in Patients With Symptomatic Intracranial Arterial Stenosis
NCT06615726Ischemic Stroke, Transient Ischemic Attack
Capital Medical University
Phase 3
1,300
Fuyang, Huainan, Suzhou, Wuhu, Beijing, Chongqing, Zhangzhou, Foshan
2024-10-10
Recruiting
Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)
NCT06602011Hepatocellular Carcinoma
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Neoadjuvant Triple Therapy for Resectable HCC
NCT06569498Resectable Hepatocellular Carcinoma
Fujian Provincial Hospital
Observational
20
Fuzhou, Xiamen, Zhangzhou
2024-09-30
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy๏ผˆRECAST-MT๏ผ‰
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning
2024-09-23
Recruiting
Efficacy and Safety of SR1375 in Adult Patients With CAP
NCT06577558Community-acquired Pneumonia
Shanghai SIMR Biotechnology Co., Ltd.
Phase 2
240
Fuyang, Beijing, Zhangzhou, Gaozhou, Guangzhou, Shantou, Yulin, Shijiazhuang
2024-09-10
Recruiting
POASAC Study (Preoperative Anemia Severity and Classification Study)
NCT06499974Anemia
Peking Union Medical College Hospital
Observational
1,000
Wuhu, Beijing, Zhangzhou, Zunyi, Chifeng, Hohhot
2024-08-02
Recruiting
Protein Molecular Characteristics and Prognosis of Cervical Neuroendocrine Tumors
NCT06276309Neuroendocrine Neoplasm, China, Women, Cervical Cancer
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Ningde, Putian, Quanzhou, Zhangzhou, Wuhan, Changsha, Nanchang
2024-02-01
Recruiting
Study on the Role of Human Serum Albumin in Large Acute Ischemic Stroke of Anterior Circulation After Thrombectomy
NCT06629116Cerebral Ischemia
Tingyu-Yi
Not applicable
100
Zhangzhou
2024-01-30
Not yet open
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127Locally Advanced or Metastatic NSCLC
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage
NCT06670456Stroke, Acute, Intracerebral Hemorrhage
De-zhi Kang
Observational
3,000
Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng
2023-11-06
Active, closed
A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion
NCT05615038Basilar Artery Occlusion, Endovascular Treatment
Beijing Tiantan Hospital
Not applicable
338
Hefei, Beijing, Anyang, Zhangzhou, Baotou
2022-11-07
Active, closed
Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT05479994Leukemia, Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
BeiGene
Phase 2
100
Hefei, Beijing, Fuzhou, Quanzhou, Zhangzhou, Lanzhou, Guangzhou, Shaoguan
2022-10-25
Recruiting
Effect of HPV Integration on Prognosis of Young Women With CIN2 in China
NCT05282095Cervical Intraepithelial Neoplasia, HPV Infection, Virus Integration, HSIL, High Grade Squamous Intraepithelial Lesions
Fujian Maternity and Child Health Hospital
Observational
300
Fuzhou, Longyan, Ningde, Putian, Sanming, Zhangzhou, Lanzhou, Shenzhen
2022-06-01
Recruiting
Oriental Research AlliaNce of Acute Ischemic Stroke Given Endovascular Treatment
NCT05024292Ischemic Stroke
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Observational
160
Zhangzhou, Shanghai
2022-01-01
Active, closed
Characteristics of Vaginal and Intestinal Microbiota and Cervical HPV Infection
NCT05003505Intestinal Microbiota, Vaginal Microbiota, HPV Infection
Fujian Maternity and Child Health Hospital
Observational
651
Fuzhou, Ningde, Quanzhou, Xiamen, Zhangzhou, Foshan, Shenzhen, Wuhan
2021-07-01
Active, closed
A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT04008030Metastatic Colorectal Cancer
Bristol-Myers Squibb
Phase 3
839
Hefei, Xiamen, Zhangzhou, Lanzhou, Foshan, Guangzhou, Nanning, Harbin
2019-08-05
Active, closed
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
NCT03221036Moderately to Severely Active Ulcerative Colitis
Takeda
Phase 3
392
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Meizhou
2017-08-03
Rows per page Showing 1–42 of 42
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/zhangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 42 of those studies with a site in Zhangzhou.

How many clinical trials are recruiting in Zhangzhou?

26 of the 42 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 7 have not yet opened recruitment, 9 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Zhangzhou), 42 studies
PhaseStudiesRecruitingShare
Phase 316638.1%
Observational8719%
Not applicable7616.7%
Phase 27516.7%
Phase 1/2327.1%
Phase 1102.4%

Most active sponsors

Lead sponsors with the most studies (Zhangzhou)
Lead sponsorStudiesRecruiting
Capital Medical University74
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.30
Fujian Maternity and Child Health Hospital32
Fujian Provincial Hospital33
Akeso21
Bristol-Myers Squibb21
BeiGene10
Beijing Anzhen Hospital11
Beijing Tiantan Hospital10
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.